These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting. Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611 [TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of a New Series of Albumin-Binding Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410 [TBL] [Abstract][Full Text] [Related]
9. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related]
10. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562 [TBL] [Abstract][Full Text] [Related]
11. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting. Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360 [TBL] [Abstract][Full Text] [Related]
12. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034 [TBL] [Abstract][Full Text] [Related]
13. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer. Li Y; Chyan MK; Hamlin DK; Nguyen H; Vessella R; Wilbur DS Nucl Med Biol; 2021 Jan; 92():217-227. PubMed ID: 32409263 [TBL] [Abstract][Full Text] [Related]
16. Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990 [TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]